N/A N=167 A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk
Percutaneous Coronary Intervention
Primary: Number of Participants With Readmission at 30 Days — 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Investigation of New Intermittent Catheter Swelling Media in Healthy Volunteers
Catheter Site Pain · Catheter Site Discomfort
Primary: Overall Discomfort During Nurse Catheterization — 1.75; 1.79 cm — p=0.88
N/A N=260 Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery
Pain, Postoperative
Primary: Percentage of Patients Who Agreed to Participate — 260; 22 Participants
Phase 2 N=7 NAD+ Precursor Supplementation in Friedreich's Ataxia
Friedreich Ataxia
Primary: Percentage of Individuals With Treatment-emergent Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 5.0. — 4 Participants
Phase 1 N=43 A Study in Healthy Men and Women to Test if Taking Different Formulations of BI 730357 Tablets Influences the Amount of BI 730357 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 730357 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5870.79; 5197.06; 19970.22…
Phase 3 N=549 Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Arthritis, Rheumatoid
Primary: Percentage of Participants With 20% Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo — 44.8; 50.7; 57.5…
Phase 1 N=15 A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞, Metformin) — 1460.83; 1434.81 hour *…
Phase 3 N=635 Relapse Prevention Study in Patients With Schizophrenia
Schizophrenia
Primary: Time to Relapse or Impending Relapse — NA; 99 Days — p=<0.0001
Phase 1 N=85 Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
Healthy
Primary: Photosensitivity Index at 24 Hours Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure) — 0.93; 1.01; 1.00; 1.04…
N/A N=27 Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants
Premature Birth · Neonatal Hypoxic Conditions
Primary: Desaturation Index — 51.7; 56.9 Number of events
Phase 2 N=77 Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
Myelodysplastic Syndromes
Primary: Hematologic Improvement of Platelets (HI-P) After 4 Months on Therapy — 71.75; 18.75 platelets (/nL)
Phase 2 N=13 ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: PSA Decline of >= 50% (PSA50) From Baseline — 7.7 percentage of participants
Phase 2 N=84 Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
Lung Neoplasm
Primary: Changes in Mean Cortical Thickness — 4.24; 7.14 percent change in mm cortical thickne
Phase 2 N=36 Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
Nasal Polyps · Asthma, Aspirin-Induced · Aspirin-exacerbated Respiratory Disease
Primary: Provocative Dose 2 (PD2) During Aspirin Challenge — 121; 142 mg
N/A N=78 Caminamos: A Smartphone App for Latinas to Connect With Walking Partners
Physical Activity
Primary: Change in Physical Activity at 4 Weeks — 43.21; 36.76 kilocalories/kg/hour